LY03020
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 18, 2025
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia
May 30, 2025
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
(clinicaltrials.gov)
- P1 | N=66 | Completed | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Feb 2025
Trial completion • Trial completion date • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia
August 16, 2024
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
(clinicaltrials.gov)
- P1 | N=66 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia
1 to 3
Of
3
Go to page
1